Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of cannabinoids to treat fibromyalgia and chronic pain, with the primary research sites for the global effort located in the U.S. and U.K. “Our team is incredibly excited to announce our entry into cannabinoid science,” president and CEO Luis Merchan was quoted in a recent article. “Commercial harvests are well underway, and it is now that we’re able to turn our attention to what we believe is the long-term future of our industry and to hedge ourselves further against the commoditization of raw cannabis materials.”
To view the full article, visit https://cnw.fm/xbrtt
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
